Search Results 101-110 of 1800 for Tracleer
Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...
Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.
Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving rituximab together with combination chemotherapy ...
This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...
The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment- ...
Havyer RD, Abedini N, Jayes RL, Matti-Orozco B, Pomerantz DH, Ansari AA. Updates in Hospital Palliative Care Am J Hosp Med. Oct-Dec 2019; 3(4).
The purpose of this pilot study is to develop and test a technology-enhanced transitional palliative care (TPC) intervention for patients and caregivers living ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.